Sienna Gestion Purchases New Stake in IDEXX Laboratories, Inc. $IDXX

Sienna Gestion purchased a new stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the 4th quarter, Holdings Channel reports. The fund purchased 2,141 shares of the company’s stock, valued at approximately $1,454,000.

Several other large investors have also recently bought and sold shares of the business. Vanguard Group Inc. raised its position in IDEXX Laboratories by 0.9% during the third quarter. Vanguard Group Inc. now owns 9,962,025 shares of the company’s stock valued at $6,364,638,000 after buying an additional 86,040 shares during the period. Elyxium Wealth LLC acquired a new position in IDEXX Laboratories during the fourth quarter valued at $3,666,459,000. State Street Corp raised its position in IDEXX Laboratories by 4.0% during the fourth quarter. State Street Corp now owns 3,656,626 shares of the company’s stock valued at $2,473,817,000 after buying an additional 138,956 shares during the period. Geode Capital Management LLC increased its position in IDEXX Laboratories by 3.5% in the 4th quarter. Geode Capital Management LLC now owns 2,583,939 shares of the company’s stock worth $1,749,380,000 after purchasing an additional 86,263 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. increased its position in IDEXX Laboratories by 63,503.9% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 1,444,445 shares of the company’s stock worth $977,210,000 after purchasing an additional 1,442,174 shares during the last quarter. 87.84% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the company. Stifel Nicolaus dropped their target price on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a research report on Tuesday, March 31st. Wall Street Zen raised IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Saturday. Citigroup assumed coverage on IDEXX Laboratories in a research report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 target price on the stock. Weiss Ratings lowered IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 11th. Finally, UBS Group dropped their target price on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 28th. Seven equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $751.00.

IDEXX Laboratories Price Performance

Shares of NASDAQ:IDXX opened at $570.00 on Tuesday. The business has a 50 day moving average price of $563.07 and a 200 day moving average price of $625.43. IDEXX Laboratories, Inc. has a twelve month low of $506.91 and a twelve month high of $769.98. The company has a market cap of $44.96 billion, a price-to-earnings ratio of 41.97, a PEG ratio of 3.07 and a beta of 1.56. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, beating the consensus estimate of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The firm had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.12 billion. During the same quarter in the prior year, the company earned $2.91 EPS. The firm’s revenue for the quarter was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Research analysts predict that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.